Athens Research & Technology;16-16-220920;Vitronectin, Human Plasma

品牌:athens research & technology

Athens Research & Technology 公司位于美国乔治亚州雅典市,从1986年以来一直致力于纯化高纯度,高活性的人类蛋白质和开发这些蛋白的多克隆抗血清。我们的常规产品包括丝氨酸蛋白酶、蛋白酶抑制剂、中性粒细胞酶、载脂蛋白、脂蛋白,血小板蛋白、转铁蛋白、免疫球蛋白等。二十年多年来,世界各地的研究人员都在使用我们公司的产品。在炎症、冠状动脉疾病、自身免疫性疾病、癌症、老年痴呆症等等研究的主要科学出版物中都能看到引用我们公司的产品。
我们提供优质,可靠的产品和出色的客户服务。我们期待着您的业务。如果需要定制研究服务,Athens Research & Technology 公司能够根据您的项目要求提供无与伦比的试剂。

Buy direct from the manufacturer.
Bulk Qty Available.

MW: 65,000 and 75,000
Extinction Coefficient: 1.38

Lyophilized from 10 mM sodium phosphate, pH 7.7

Vitronectin and plasminogen activator inhibitor type 1 are proteins that interact in the circulatory system and pericellular region to regulate fibrinolysis, cell adhesion, and migration. Plasminogen activator inhibitor type 1, a serine proteinase, through its binding to the plasma protein vitronectin, influences processes that are key regulators of hemostatic process, for example, thrombosis and wound healing. In addition the vitronectin and plasminogen activator inhibitor type 1 complex regulates binding of blood platelets and cells to extracellular substrata in events like tumor metastasis. The plasma concentration of vitronectin is 200 to 400 μg/ml.

Storage: -20°C

Purity: approximately 95% by SDS-PAGE

Prepared from plasma shown to be non reactive for HBsAg, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA approved tests.

Athens Research & Technology products are laboratory reagents and are not to be administered to humans or used for any drug purpose. For research or further manufacturing use only.

Product Citation:
Wihadmadyatami H, R?der L, Bergh?fer H, Bein G, Heidinger K, Sachs UJ, Santoso S. Immunisation against IIb3 and v3 in a type 1 variant of Glanzmann's thrombasthenia caused by a missense mutation Gly540Asp on 3. Thromb Haemost. 2016 Aug 1;116(2):262-71. doi: 10.1160/TH15-12-0982. Epub 2016 Apr 21.